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Renin-angiotensin blockade lowers MCP-1 expression in
diabetic rats
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Renin-angiotensin blockade lowers MCP-1 expression in dia- to precede the earliest manifestations of diabetic
betic rats. nephropathy [1–3]. In rats made diabetic with streptozo-
Background. Glomerular macrophage accumulation in dia- tocin (STZ) and maintained at moderate levels of hyper-betes implicates monocyte recruitment mechanisms in the
glycemia by daily insulin injections, glomerular hyper-pathogenesis of diabetic nephropathy. To test the hypothesis
filtration, caused by elevations of glomerular perfusionthat overexpression of monocyte chemoattractant protein-1
(MCP-1), a monocyte chemoattractant, is attenuated by renin- and intracapillary hydraulic pressure (glomerular capil-
angiotensin system (RAS) inhibition, we assessed expression lary hypertension), likewise presages glomerular injury
of genes regulating monocyte transmigration in the glomeruli [4]. Both glomerular capillary hypertension and the sub-of diabetic rats.
sequent development of glomerular injury are dependentMethods. Competitive reverse transcription-polymerase chain
on an intact renin-angiotensin system (RAS), as revealedreaction (RT-PCR) was used to semiquantitate mRNA expres-
sion in glomeruli harvested by sieving at serial intervals after by earlier studies from this laboratory showing that treat-
the induction of diabetes by streptozotocin in Munich-Wistar ment with angiotensin-converting enzyme inhibitors
rats. Although subject to limitations, competitive RT-PCR pro-
(ACEIs) [5], alleviated glomerular capillary hyperten-vides an objective measure suited to the minute quantities of
sion and prevented the development of diabetic ne-RNA extractable from glomerular isolates.
Results. Time-dependent elevation of MCP-1 expression phropathy in STZ rats, independent of glycemic control.
was dramatically suppressed by treatment with the angiotensin- These studies established the experimental basis for the
converting enzyme inhibitor enalapril or the AT1 receptor antag- first successful large-scale clinical trial of ACEI in typeonist candesartan, and was closely associated with effects on
I diabetic patients [6].proteinuria and glomerular macrophage number. By contrast,
Glomerular injury occurring in the context of angio-no sustained suppression of the cell adhesion molecules inter-
cellular adhesion molecule-1 or vascular cell adhesion mole- tensin-dependent processes, including augmented glo-
cule-1 or the classic MCP-1 stimulators tumor necrosis factor-a merular hemodynamics, may involve mononuclear cells
or interleukin-1b followed RAS inhibition, and suppression of
and an array of cytokines and other proinflammatorytransforming growth factor-b1 expression was transient.
molecules. Evidence is accumulating that supports theConclusion. These data suggest that glomerular macrophage
recruitment in experimental diabetes is largely determined by hypothesis that macrophages and macrophage products
angiotensin-stimulated MCP-1 expression. We conclude that play a significant role not only in inflammatory glomeru-
the RAS is an important regulator of local MCP-1 expression, lar and interstitial diseases but also in the pathogenesiseither directly or through glomerular hemodynamic effects, and
of glomerulosclerosis unrelated to active glomerulitis [7–that our data strongly implicate macrophage recruitment and
10]. Increased numbers of glomerular macrophages haveactivation in the pathogenesis of early diabetic glomerular injury.
been observed in rats with experimental diabetes [11],
as well as in biopsy samples of kidneys from diabetic
In patients with recent onset diabetes mellitus (DM), humans [12]. These associations foster speculation that
glomerular hyperfiltration is frequently present and tends infiltration of the glomerular mesangium by macrophages
may also contribute to the development of diabetic
glomerulopathy. Moreover, the expression of monocyteKey words: diabetic nephropathy, monocyte transmigration, enalapril,
candesartan, proteinuria, macrophage recruitment, glomerular injury. chemoattractant protein-1 (MCP-1), a key macrophage
chemoattractant and activator [13], is known to be up-Received for publication August 6, 1998
regulated in vascular smooth muscle by angiotensin-in-and in revised form March 23, 1999
Accepted for publication April 7, 1999 duced hypertension in vivo and by fluid shear stress and
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hypothesized that in early diabetes, increased activity of controls. All rats were allowed free access to standard rat
chow (Ralston-Purina, St. Louis, MO, USA) ad libitum.the local RAS induces the expression of MCP-1, which,
From day 2, the diabetic rats received a daily subcuta-in turn, enhances recruitment of macrophages into the
neous injection of 3.0 to 4.5 U human recombinant long-mesangial and tubulointerstitial areas from the circulat-
acting insulin (Novolin L; Novo Nordisk A/S, Bagsvaerd,ing monocyte pool. Activated macrophages, through a
Denmark), as required to maintain the blood glucosevariety of pleiotropic products, are then poised to con-
concentration between 200 and 350 mg/dl, reflectingtribute to the development of renal injury. To address
“moderate” hyperglycemia, conditions under which itthis hypothesis, we counted glomerular macrophages and
has been established that glomerular hyperfiltration–used competitive reverse transcription-polymerase chain
glomerular capillary hypertension is present [4]. At dayreaction (RT-PCR) techniques to provide a semiquanti-
7, the diabetic rats were divided into three groups (Atative assessment of the expression of MCP-1 and related
through C). Group A (N 5 30) and group D (nondiabeticmolecules in glomeruli isolated from STZ-induced dia-
rats, N 5 19) received vehicle alone. Group B (N 5 24)betic rats kept moderately hyperglycemic by daily insulin
received the angiotensin I-converting enzyme inhibitorinjection. Previous studies from this laboratory using
enalapril maleate (Merck & Co. Inc., Rahway, NJ, USA).similar diabetic protocols have established the presence
Group C (N 5 25) received the angiotensin II typeof glomerular hypertension in this model and that the
1-specific receptor antagonist candesartan (TCV-116;magnitude of proteinuria is a reliable predictor of the
Takeda Chemical Industries, Osaka, Japan). Both enala-extent of diabetic glomerulosclerosis that eventually su-
pril and candesartan were added to the drinking waterpervenes [4, 5, 16]. We therefore sought to assess the
at 100 mg/liter. As candesartan is poorly soluble in water,effects of inhibition of the RAS both on serial determina-
a vehicle consisting of sodium bicarbonate (2 mm), etha-tions of macrophage infiltration and MCP-1 expression
nol (0.1%), and polyethylene glycol 400 (0.1%) was usedin relationship to proteinuria over the first four months
to ensure solubility. Water intake, averaging 40 ml/day,of STZ-induced diabetes in Munich-Wistar rats. These
did not differ among the diabetic groups. Blood glucosefactors were studied in relationship to tumor necrosis
concentrations of diabetic rats were monitored twicefactor-a (TNF-a) and interleukin (IL)-1b expression,
weekly. Systolic blood pressure (SBP) and urinary pro-two classic inducers of MCP-1 [17, 18]; intercellular adhe-
tein excretion rates (UprotV) were determined every threesion molecule-1 (ICAM-1) and vascular cell adhesion
weeks by the tail cuff method and by precipitation withmolecule-1 (VCAM-1), monocyte adhesion molecules;
sulfosalicylic acid, respectively.and transforming growth factor-b (TGF-b), a fibrogenic
At months 1, 2, and 4 after induction of DM, rats infactor that can be derived from macrophages or constitu-
each group were anesthetized with an intraperitoneal
tive glomerular cells and has been proposed to serve as
injection of pentobarbital (50 mg/kg), and the right kid-
a link between glomerular capillary hypertension and ney was excised and weighed immediately. One small
glomerulosclerosis [19–21]. piece of kidney cortex was shaved off and snap frozen
The findings show that up-regulated expression of glo- in liquid nitrogen for immunohistology. The remaining
merular MCP-1 in diabetic rats occurs through angioten- cortex from both kidneys was used for isolating glomer-
sin-dependent processes and that both overexpression of uli, prepared by the sequential sieving method [22].
MCP-1 and increased macrophage infiltration are closely Briefly, cortical slices were minced using surgical clippers
associated with the development of proteinuria. This and pressed with a rubber plunger through a stainless
implies that macrophages, recruited by MCP-1, may con- steel screen of 200 mm diameter mesh with frequent
tribute, in part, to the pathogenesis of glomerulopathy flushing with ice-cold phosphate-buffered saline (PBS).
in experimental diabetes. Glomeruli were then rinsed with PBS through screens
of 100 and 75 mm diameter meshes. Glomeruli recovered
from the 75 mm diameter mesh were resuspended in PBSMETHODS
and collected by centrifugation. The purity of sieved
Experimental design glomeruli was verified by light microscopy, confirming
Studies were undertaken in 98 male Munich-Wistar a preparation consisting of more than 95% glomeruli.
rats weighing 260 to 290 g (Simonsen Laboratories, Gil- Glomerular isolation as described earlier here was com-
roy, CA, USA). Of these, 79 rats received a single intra- pleted within 20 minutes of removing the kidney. RNA
venous injection of STZ (50 mg/kg body wt; Sigma, St. extraction proceeded immediately thereafter.
Louis, MO, USA) dissolved in sodium citrate buffer (pH
Competitive reverse transcriptase-polymerase4.5) at day 0. The diabetic state was confirmed 48 hours
chain reactionlater by the determination of blood glucose concentra-
tions .250 mg/dl. The remaining 19 rats received an Total RNA was extracted from isolated whole glomer-
uli by the acid guanidinium isothiocyanate-phenol chlo-injection of buffer (group D) and served as nondiabetic
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Table 1. Summary of primer sequences and PCR conditions
Size Annealing
Primer Sense sequence Antisense sequence (bp) temp. 8C
MCP-1 ATGCAGGT C T C TGT CACG C TAGT T C T C TGT CATAC T 447 55
TGF-b1 C T T CAGC T CCACAGAGAAGAAC TGC CACGAT CATGT TGGACAAC TGC T CC 298 64
TNF-a TAC TGAAC T T CGGGGTGAT TGGT CC CAGCC T TGT CCC T TGAAGAGAACC 295 60
IL-1b TGATGT T CCCAT TAGACAGC GAGGTGC TGATGTACCAGT T 378 55
ICAM-1 AGAAGGAC TGC T TGGGGAA CC T C TGGCGGTAATAGGTG 332 60
VCAM-1 C TGACC TGC TGC T CAAGTGATGG GTGT C T CCC T C T T TGACGC T 260 60
CSF-1 AGCCAT CGAGACCC T CAGACAT TGG TAGTGAGT CCC T TGCCAGGT T C TGG 451 64
b-actin T TGTAACCAAC TGGGACGATATGG GAT C T TGAT C T T CATGGTGC TAGG 764 60
roform extraction method [23] using RNAzol B solution subjected to gel electrophoresis (5% polyacrylamide),
(TEL-TEST Inc., Friendswood, TX, USA). RNA was and DNA bands were visualized under ultraviolet light
quantitated by determination of ultraviolet absorbance after ethidium bromide staining (0.05 mg/ml for 10 min)
at 260 nm, and its purity was assessed by measuring the and photographed (Fig. 1A). Densities of competitive
optical density ratio at 260 and 280 nm. For preparation mimic and target DNA bands were measured by scan-
of cDNAs, 4 mg of heat-denatured RNA was used in ning densitometry using ScanJet 4c (Hewlett Packard,
the RT reaction. The entire sample in a total volume of Corvallis, OR, USA) with Adobe Photoshop software
20 ml contained 4 mg of RNA; 0.5 mm each of dATP, (Adobe Inc., Mountainview, CA, USA). The ratios of
dCTP, dGTP, and dTTP (Pharmacia Biotech Inc., Pisca- the densities of the respective bands, corrected by the
taway, NJ, USA); 0.6 mg oligo-d(T)12-18 (Pharmacia Bio- nucleotide lengths of each amplified DNA fragment,
tech Inc.); 40 U RNasin ribonuclease inhibitor (Promega, were plotted on a logarithmic graphic chart to establish
Madison, WI, USA); 400 U M-MLV reverse tran- a linear relationship of the ratios over serial dilutions of
scriptase (Life Technologies, Gaithersburg, MD, USA) template. The constant, A, was derived from the slope
in a buffer of 50 mm Tris-HCl (pH 8.3); 75 mm KCl, 3 of the plot. Thus, the absolute amount of RNA from an
mm MgCl2, and 10 mm dithiothreitol. The solution was unknown sample (Cs) was calculated using the following
incubated for 60 minutes at 378C and then boiled at 958C equation:
for five minutes to arrest the reaction.
Cs 5 [Cm · (Ds/Dm)](1/A)Preparations of cDNA were then used as a substrate
for competitive PCR reaction using competitive DNA where Cm is the concentration of the DNA mimic used
mimics and oligonucleotide primer sets (Genosys Bio- in the RT-PCR assay, and Ds and Dm are the corrected
technologies, Inc., Woodlands, TX, USA). Competitive densities of the target DNA band and its competitive
DNA mimics for each factor were constructed using a MIMIC, respectively. Figure 1B shows the effect of dou-
PCR MIMIC Construction Kit (Clontech Laboratories, bling the quantity of template in the starting reaction.
Inc., Palo Alto, CA, USA). Primer sets were designed for This confirmed that the assay behaved in a linear fashion
rat MCP-1, TGF-b1, TNF-a, IL-1b, ICAM-1, VCAM-1, over the range required for the samples. An absolute
colony stimulating factor-1 (CSF-1), and b-actin based amount of RNA for b-actin, a housekeeping gene, was
on previously reported cDNA sequences [24–29]. An also calculated in the same manner, and was used as an
equal volume of each cDNA solution was used for ampli-
internal control. Expression of cytokine mRNA for eachfication in 20 ml of reaction mixture containing competi-
sample was then expressed as an arbitrary ratio of thetive DNA mimic, 0.5 pmol primer sets; 0.5 U Taq DNA
quantity of RNA to that of b-actin (Fig. 5). RNA waspolymerase (Pharmacia Biotech Inc.); 250 mm each of
also subjected directly to amplification in a control exper-dATP, dCTP, dGTP, and dTTP (Pharmacia Biotech
iment to survey for contamination by genomic DNA.Inc.) in a buffer of 10 mm Tris-HCl (pH 9.0) and optimal
PCR reactions for each factor were repeated twice andconcentration of MgCl2. PCR was performed using a
were found to not differ appreciably from one another.Peltier Thermal Cycler (MJ Research Inc., Watertown,
This method has been deemed as accurate as scintillationMA, USA). Optimal PCR conditions such as concentra-
counting of radiolabeled PCR products [30].tion of competitive DNA mimic, annealing temperature,
and amplification cycles were determined for each factor
Immunohistologyin preliminary studies. Amplification was initiated with
To assess and localize protein expression of TGF-bincubation at 948C for two minutes followed by amplifi-
and MCP-1 and to count infiltrating macrophages, immu-cation cycles as follows: 948C for 15 seconds, annealing
nohistology was performed. Cryostat sections (5 mmtemperature for 30 seconds, and 728C for 1 minute. Se-
thickness) were prepared from snap-frozen kidney cor-quences of oligonucleotide primer sets and optimal con-
ditions are listed in Table 1. PCR products (7 ml) were tex stored at 2708C. After fixation in cold acetone for 10
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Fig. 1. Example of semiquantification of gene expression by competitive RT-PCR. (A) Representative photographs of polyacrylamide gels from
RT-PCR reactions for monocyte chemoattractant protein-1 (MCP-1) and b-actin. Serial dilutions of cDNA template and typical samples from
candesartan-treated (D-can) or untreated (D-veh) diabetic rats and from nondiabetic controls (Con) at month 2 are shown. (B) Exponential
increment of the quantities of template in the starting reaction of PCR for b-actin confirmed that the assay performed in a near linear fashion
over the range required by the samples.
minutes, sections were air dried and stained for cytokines (DAB) in PAP. The tissue sections were counterstained
with Mayer’s hematoxylin and were dehydrated andusing the indirect immunofluorescence (IIF) method, as
reported by Hancock, Becker and Atkins, and for infil- coverslipped. The mean numbers of glomerular ED1-
positive cells in a sample were determined by assessingtrating cells using the peroxidase-antiperoxidase (PAP)
method (Sigma) [31]. After washing in Tris-buffered sa- 20 glomeruli per kidney.
line (TBS, pH 7.6), sections were blocked sequentially
Statistical analysiswith 0.3% H2O2 in TBS and 2% normal goat serum
(Sigma). Kidney sections from rats in all groups were The results are expressed as mean 6 sem. Statistical
comparisons among groups were performed by one-wayprepared at the same time and were assessed in a blinded
fashion [31]. Briefly, sections were incubated at 48C over- analysis of variance with post hoc testing as appropriate.
Regression analysis between glomerular mRNA expres-night with antimouse TGF-b monoclonal antibody (Gen-
zyme, Cambridge, MA, USA), recognizing TGF-b1, -2 sion of cytokines and physiological data was performed
using standard formulae. To obviate assumptions of lin-and -3, or hamster antimouse MCP-1 monoclonal anti-
body (PharMingen, San Diego, CA, USA) as primary earity, mRNA expression ratios were treated as categori-
cal data for statistical analysis by one-way analysis ofantibodies. Thereafter, fluorescein isothiocyanate (FITC)-
conjugated goat antimouse or antihamster secondary an- variance. Statistical comparisons of intensity scores for
immunohistology were performed by nonparametrictibodies (Vector Laboratories, Burlingame, CA, USA)
were applied to the sections for 60 minutes, respectively. Kruskal–Wallis testing followed by the Mann–Whitney
rank test. Statistical significance was accepted at P ,After washing and cover slipping, glomerular immuno-
staining was scored semiquantitatively while viewing un- 0.05.
der the fluorescence microscope as follows: 0 5 none;
11 5 isolated staining in less than 25% of the glomeruli;
RESULTS
21 5 staining in 25 to 50% of the glomeruli; 31 5
Background datastaining in 50 to 75% of the glomeruli; 41 5 staining
present in more than 75% of the glomeruli. For the Body weight, blood glucose concentration, kidney
weight, and SBP data at each time point for groups Astaining of macrophages, specimens were incubated with
mouse antirat monocyte/macrophages monoclonal anti- to D are summarized in Table 2. Blood glucose concen-
trations did not differ among the groups at the beginningbody (ED1; Serotec, Oxford, UK) for one hour at 48C.
Goat antimouse secondary antibody was then applied of the study (data not shown). In group A, moderate
hyperglycemia was confirmed by blood glucose levelsto the sections for 60 minutes. PAP complexes were
visualized after incubation with 39,39-diaminobenzidine that were significantly higher than those in nondiabetic
Kato et al: Glomerular MCP-1 expression in diabetic rats 1041
Table 2. Background data
Time in months
Variables Group 1 2 4
Rats tested (N)
A 11 9 10
B 10 8 6
C 10 7 8
D 5 6 8
Blood glucose mg/dl
A 267616a 265613a 262617a
B 308620a 284620a 321635a
C 289620a 306621a 312619a
D 8161 77 64 74 65
Body weight g
A 28365a 30065a 31666a
B 27364a 28266a 290618a
C 26969a 28869a 29969a
D 31568 336 67 362 69
Kidney weight g
Fig. 2. Time course difference of urinary protein excretion rate inA 1.3260.06 1.57 60.06a 1.5360.06a
nondiabetic rats (h) and untreated (j), enalapril-treated ( ), andB 1.1360.04 1.19 60.04b 1.4260.05
candesartan-treated ( ) diabetic rats. Renin-angiotensin system (RAS)C 1.1360.06 1.16 60.06b 1.4060.07
inhibition suppressed urinary protein excretion rate in diabetic rats.D 1.0960.04 1.18 60.04 1.27 60.02
*P , 0.05 vs. untreated diabetic group.Kidney weight/body weight ratio %
A 0.4660.02a 0.5360.06a 0.4860.01a
B 0.4160.01 0.42 60.01b 0.5060.04b
C 0.4260.02 0.40 60.03b 0.4760.03b
D 0.3560.01 0.35 60.01 0.35 60.01
candesartan-treated diabetic rats (group C) at all timeSystolic blood pressure mm Hg
A 13163 137 65 131 64 points when compared with untreated diabetic rats
B 10963b 11766 115 67 (group A). Blood pressure-lowering effects were signifi-
C 10966b 10568a,b 10667a,b
cantly greater in diabetic rats receiving candesartan ver-D 12767 133 63 136 63
sus enalapril over four months when analyzed by one-Definitions of groups are: Group A, untreated diabetic rats; group B, enalapril-
treated diabetic rats; group C, candesartan-treated diabetic rats; group D, non- way analysis of variance for repeated measures (F 5 7.2,
diabetic rats. Values are means 6 sem. P , 0.05).a P , 0.05 groups A, B or C vs. group D
b P , 0.05 groups B or C vs. group A Urinary protein excretion rates are shown in Figure
2. In untreated diabetic rats, UprotV increased gradually
from months 1 to 4 after the onset of diabetes. When
compared with untreated diabetic rats, UprotV of enala-
rats (group D). The blood glucose concentrations of dia- pril-treated rats was significantly lower at months 1 and
betic rats treated with enalapril (group B) or candesartan 4, whereas UprotV in candesartan-treated rats averaged
(group C) did not differ significantly from those of un- values that were significantly lower at all time points
treated diabetic control rats (group A) and were stable studied. Interestingly, at each time point, RAS inhibition
during the four-month period of the study in all groups. with either enalapril or candesartan was associated with
Mean body weights were similar among the groups at levels of UprotV that were even lower than those of nondi-
the time of STZ injection. At each subsequent time point abetic control rats. This tendency was also observed in
studied, body weights were significantly lower in diabetic earlier studies of captopril [32] or losartan [33] in experi-
rats (groups A through C) than nondiabetic rats (group mental diabetes.
D), but did not differ among groups A through C. De-
Glomerular macrophagesspite lower body weights, renal hypertrophy was appar-
ent in untreated diabetic rats at all time points, with Mean numbers of glomerular ED1-positive cells did
group A rats showing a significantly greater mean renal not differ among groups A to D at one month. Numbers
mass and kidney weight/body weight ratios compared of ED1-positive cells were, however, significantly in-
with the respective values for group D. Although unad- creased in untreated diabetic rats at two months of diabe-
justed kidney weights of groups B and C were not sig- tes versus nondiabetic rats (3.60 6 0.60 vs. 0.83 6 0.08
nificantly higher than those for group D, kidney weight/ cells/glomerular profile in groups A and D, respectively,
body weight ratios were significantly higher in groups B P , 0.05; Figs. 3 and 4). This increase was sustained at
and C at four months when compared with group D. four months (5.36 6 0.72 vs. 1.77 6 0.46 cells/glomerular
Mean values of SBP were similar in groups A and D at profile, P , 0.05). The increased macrophage infiltration
all time points. SBP was significantly lower in enalapril- at months 2 and 4 was greatly suppressed by treatment
with enalapril or candesartan to levels comparable totreated diabetic rats (group B) at one month and in
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The expression of the classic inducers of MCP-1,
TNF-a, and IL-1b, appeared discordant with temporal
patterns of MCP-1 expression. Up-regulation of glomer-
ular TNF-a expression was not clearly suppressed by
treatment at any stage (Fig. 5C). Moreover, glomerular
IL-1b mRNA expression did not differ between nondia-
betic and diabetic rats, and expression was not reduced in
rats receiving enalapril or candesartan, when compared
with untreated diabetic rats (Fig. 5D). Indeed, higher
expression of TNF-a and IL-1b was observed in enala-
pril-treated diabetic rats versus untreated diabetic group
at four months. Thus, it appears unlikely that the ob-
served changes in MCP-1 expression could be attributed
to altered TNF-a or IL-1b expression.
A clear but transient suppression of TGF-b1 overex-
pression at two months was observed with enalapril
Fig. 3. Mean numbers of ED1-positive cells (monocyte/macrophages) or candesartan treatment versus no treatment, but not
in glomeruli of nondiabetic rats (h), enalapril-treated ( ), candesartan-
at four months, at which time levels of glomerulartreated ( ), and untreated (j) diabetic rats. The increased infiltration
TGF-b1 expression were indistinguishable among theof these cells, evidenced at months 2 and 4, was significantly suppressed
by RAS inhibitors. *P , 0.05 vs. untreated diabetic group. groups (Fig. 5B).
Glomerular CSF-1 mRNA expression was signifi-
cantly increased at one month, a response that tended
to be suppressed by drug treatment at months 1 and 2those of the nondiabetic groups (B, 1.37 6 0.24; C,
(Fig. 5G). At four months, however, levels of expression1.39 6 0.23 cell/glomerular profile at two months, and
returned toward baseline levels, and the differences be-B, 2.50 6 0.58; C, 2.79 6 0.71 cell/glomerular profile at
tween treated and untreated diabetic rats abated.four months). Macrophage infiltration in periglomerular
(Fig. 4) and tubulointerstitial (data not shown) regions Immunohistological studies
was also observed in untreated diabetic rats. Similarly,
Increased immunostaining for MCP-1 was observedin diabetic rats receiving RAS inhibitors, fewer macro-
in glomeruli of untreated diabetic rats from four months,
phages were noted in tubulointerstitial areas. confirming that protein expression tracks with gene ex-
pression. Strong focal and segmental staining for MCP-1Expression of mRNA for cytokines and growth factors
was seen in glomerular tufts of untreated diabetic kid-in glomeruli of diabetic rats
neys (Fig. 6A), whereas staining in glomeruli of enalapril-
Among the factors analyzed in this study, levels of or candesartan-treated rats, by contrast, was much less
expression of MCP-1, TGF-b1, and TNF-a were in- intense (Fig. 6B), resembling nondiabetic controls (Fig.
creased in glomeruli by two months after the onset of 6C). Scoring of the glomerular staining for MCP-1, con-
diabetes (Fig. 5 A–C). Although mRNA for ICAM-1 ducted in a blinded fashion, confirmed that the intensity
displayed tendencies toward increased levels of expres- of staining for MCP-1 was increased in untreated diabetic
sion, ICAM-1 and VCAM-1 showed no statistically sig- rats and was significantly suppressed by treatment with
nificant changes in expression over time and did not enalapril or candesartan (Fig. 7). Immunoreactivity to
differ between diabetic and nondiabetic groups (Fig. 5 MCP-1 was also identified by weak staining in tubuloin-
E, F). Moreover, RAS inhibition had no significant effect terstitial regions of untreated diabetic kidneys at months
on the expression of ICAM-1 or VCAM-1. Although 2 and 4 (data not shown). Similarly, tubulointerstitial
high levels of MCP-1 expression were sustained at four immunostaining for MCP-1 was diminished in rats re-
months in untreated diabetic rats, the levels of MCP-1 ceiving RAS inhibitors. Staining for TGF-b also con-
expression were not statistically different from age- firmed the results of its mRNA expression, in which
matched, nondiabetic controls because of time-related significant suppression of glomerular TGF-b staining be-
increases in MCP-1 expression. However, increases in tween untreated and treated diabetic groups was ob-
MCP-1 expression were completely suppressed by treat- served at two months but not four months (data not
ment with enalapril or candesartan at two and four shown).
months after the induction of diabetes (Fig. 5A). Inter-
Correlation of mRNA expression toestingly, as with proteinuria, the expression of MCP-1
physiological parametersmRNA was even lower in enalapril- or candesartan-
treated diabetic rats than nondiabetic time controls at The previously mentioned data suggested that certain
factors among those examined were more clearly associ-months 2 and 4.
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Fig. 4. Immunohistological staining for ED1-
positive monocyte/macrophage cells at two
months in untreated diabetic kidney. Positive
staining was observed in the glomerulus
(arrows) and in the periglomerular region (ar-
rowhead). Hematoxylin as counterstaining is
shown (3400).
Table 3. Correlation of glomerular mRNA expression with urinary accounts for a large proportion of end-stage renal disease
protein excretion rate (UprotV) and kidney weight/body weight in developed nations [34]. Considerable progress has
Regression coefficients (r) been made in understanding the pathophysiology of dia-
Variables MCP-1 TGF-b1 TNF-a betic nephropathy, and several theories have been ad-
vanced to explain the mechanisms of glomerular injuryUprotV 0.62a 0.20 0.15
Kidney wt/body wt 0.13 0.46a 0.59a in diabetes, implicating factors as diverse as glomerular
Regression analysis was performed between mRNA expression ratio to hemodynamics [4, 16], growth mediators [35–37], and
b-actin and UprotV or Kidney wt/body wt. mRNA expression of IL-1b, ICAM-1, glycosylation of glomerular structures [38]. PreviousVCAM-1 and CSF-1 did not show any significant correlations either with UprotV
or with kidney wt/body wt (data not shown). work from our laboratory has established the importance
a P , 0.05 by categorized one-way ANOVA of hemodynamic factors and angiotensin-dependent pro-
cesses in the pathogenesis and progression of chronic,
diabetic renal disease [4, 16]. Despite this progress, the
ated with glomerular injury than others. To define this molecular mediators of glomerular injury in diabetes
better, we performed correlational analyses of glomeru- remain largely unidentified. In view of recent evidence
lar mRNA expression of cytokines to urinary protein that angiotensin-induced hypertension stimulates vascu-
excretion rate, SBP, and kidney weight, using data from lar smooth muscle to express MCP-1 [14], coupled with
all time periods. To obviate assumptions of linearity, the observation that the glomerular macrophage number
mRNA expression ratios were treated as categorical data increases in diabetes [11, 12], we sought to identify mole-
for statistical analysis. Robust and significant associa- cules involved in monocyte recruitment in STZ-induced
tions were found between glomerular MCP-1 mRNA diabetes before the structural lesions of overt diabetic
expression and urinary protein excretion rate (R 5 0.62, nephropathy develop [4, 16, 32].
P , 0.05; Table 3). By contrast, expression of other The most dynamic response observed was for MCP-1
factors did not correlate significantly with this parameter. expression, both in terms of magnitude of mRNA expres-
TGF-b1 and TNF-a expression correlated with the kid- sion in the glomeruli of untreated diabetic rats and the
ney weight/body weight ratio (R 5 0.46 and 0.59, respec- extent of its dramatic suppression in diabetic rats receiv-
tively, P , 0.05). Other factors, on the other hand, did not ing RAS inhibitors. By immunohistochemistry, similar
correlate with this parameter. SBP showed no significant responses were noted in both glomerular and tubuloin-
correlations with any of the factors studied (data not terstitial areas. Patterns of intensity of glomerular MCP-1
shown).
expression over time bore a close relationship to those of
macrophage number and the magnitude of proteinuria.
DISCUSSION Interestingly, lowered MCP-1 mRNA expression in the
diabetic groups receiving RAS inhibitors mimicked theDiabetic nephropathy is the single most common
cause of end-stage renal disease in the United States and suppression of proteinuria to levels lower than those
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Fig. 5. Expression of mRNA for MCP-1 (A), TGF-b1 (B), TNF-a (C), IL-1b (D), ICAM-1 (E), VCAM-1 (F), and CSF-1 (G) in glomeruli of
untreated (j), enalapril-treated ( ), and candesartan-treated ( ) diabetic rats, and nondiabetic control (h) rats. Data were expressed as arbitrary
ratios of the amount of expressed mRNA of each factor to that of b-actin, as described in the Methods section. Drug treatment suppressed the
expression of MCP-1 at two and four months and TGF-b1 at two months. *P , 0.05 vs. untreated diabetic group.
found in age-matched, nondiabetic control rats, although Park et al, J Am Soc Nephrol 5:971, 1994; abstract; Sassy-
Prigent et al, J Am Soc Nephrol 7:1878, 1996), the fullsuch patterns were not observed by immunohistochemi-
cal scoring of glomerular staining for MCP-1. MCP-1 significance of this factor in diabetic glomerular injury
is not well understood. MCP-1, a molecule producedmRNA expression at four months in untreated diabetic
rats remained elevated, but was not significantly higher by mesangial cells [18] but also derived from activated
macrophages [13], is thought to participate in the patho-than nondiabetic control rats because of a time-depen-
dent increase in MCP-1 mRNA levels in nondiabetic genesis and progression of inflammatory glomerular and
tubulointerstitial diseases via recruitment and activationcontrols. Immunohistological study of MCP-1, on the
other hand, suggested significant differences between of mononuclear cells [39, 40]. Furthermore, our data
suggest that glomerular MCP-1 expression is stimulatedthese two groups, in keeping with the number of glomer-
ular macrophages. Such discrepancies between the re- by the RAS. Specifically, the similarity of actions of both
angiotensin II type I receptor antagonist and ACEI insults of mRNA versus protein expression could be due
to either the post-transcriptional regulation of the mole- this respect indicate an angiotensin II-dependent pro-
cess, mediated via AT1 receptors. This could be a directcule or the accumulation effect during four months. Fur-
ther studies are needed to resolve these issues. effect of angiotensin II on the cells synthesizing MCP-1
or an indirect effect, via an angiotensin-dependent pro-Although elevated glomerular expression of MCP-1
in diabetic rats has been reported previously (abstract; cess with direct bearing on the glomerulus, such as the
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Fig. 6. Immunofluorescence photomicrographs for MCP-1 (A–C) in the glomeruli of untreated diabetic (A), candesartan-treated diabetic (B),
and nondiabetic control (C) rats at month 2 after diabetic onset. Intensified glomerular staining for these factors in the diabetic kidney was
suppressed by drug treatment (3400).
maintenance of glomerular capillary hypertension. The lus to MCP-1 expression acts in this setting. Recent stud-
ies provide precedent for MCP-1 expression induced byincreased expression of MCP-1 appears much less likely
to be dependent on expression of TNF-a or IL-1b be- mechanical stimuli: Vascular endothelial cells in culture
subjected to fluid shear stress increase their expression ofcause the patterns of expression of these molecules bear
little relationship to those of MCP-1 in untreated or MCP-1 [15]; systemic hypertension produced by chronic
angiotensin II infusion is associated with increased aortictreated rats. We propose instead that a mechanical stimu-
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was assessed in order to address the latter possibility. A
transient increase in CSF-1 expression occurred at only
one month, whereas macrophage numbers increased
progressively throughout the study period, lowering the
probability that macrophage numbers increased through
CSF-1–induced proliferation. Similarly, although RAS
inhibition suppressed the CSF-1 response at one month,
the effect was not sustained. We therefore doubt that in
situ proliferation accounts for the majority of glomerular
macrophages identified.
We studied the glomerular expression of TGF-b, as
this growth factor may be synthesized by activated mac-
rophages or glomerular cells and has been implicated as
an effector of fibrosis in a variety of settings, including
diabetic nephropathy [21, 37, 42–45], as well as nondia-
betic nephropathies [42, 46–49]. Although an increase
in TGF-b expression over time was observed in the un-
Fig. 7. Immunohistological staining scores for MCP-1 in glomeruli of treated diabetic group, the response to RAS inhibitionnondiabetic rats (h) and enalapril-treated ( ), candesartan-treated
was ambivalent, with the suppression at two months be-( ), and untreated (j) diabetic rats at two months. In treated diabetic
groups, the elevated glomerular expression of MCP-1 was suppressed ing lost at four months. This indicates first that angioten-
to the level similar to the nondiabetic control group. *P , 0.05 vs. sin-independent mechanisms predominate in stimulating
untreated diabetic group.
TGF-b at four months, and second that TGF-b expres-
sion is not invariably associated with indices of glomeru-
lar injury, in this case proteinuria. Several known stimuli
could account for the observed up-regulation of TGF-b.MCP-1 expression [14], a situation that is analogous to
the relationship between glomerular capillary hyperten- Angiotensin II may promote TGF-b synthesis either di-
rectly [50, 51], or possibly indirectly, via raised glomeru-sion and cells in the glomerulus in STZ diabetic rats. We
therefore speculate that the mechanical effects imparted lar capillary hydraulic pressure [19]. Either mechanism
could therefore account for the increased expression atto glomerular cells by glomerular capillary hypertension
in early diabetes may account for a significant proportion two months. Chronic hyperglycemia, through accumula-
tion of advanced glycation end-products (AGEs), mayof the increased MCP-1 expression we observed in glo-
merular isolates. An alternative explanation, that is, of a stimulate TGF-b expression [52–55], which could be con-
sistent with the angiotensin-independent expression ob-direct receptor-mediated effect of angiotensin II, cannot
entirely be excluded and may apply in tubulointerstitial served at four months. Finally, TGF-b is implicated as
a mediator of glomerular and renal hypertrophy [43, 56],areas, but it is noteworthy that in the study on vascular
smooth muscle, the control of the angiotensin-induced as well as glomerular sclerosis. We observed a close
association of TGF-b expression with kidney weight assystemic hypertension by hydralazine substantially re-
duced MCP-1 expression, consistent with an effect of an index of hypertrophy. Whether this signifies closer
involvement of TGF-b with glomerular hypertrophyincreased pressure rather than a direct effect of angioten-
sin II [14]. rather than injury in this model remains a subject for
future studies. Of interest is our finding that glomerularDespite the significant reduction of MCP-1 mRNA
expression by blockade of the RAS to levels lower than TNF-a expression, which is unresponsive to RAS inhibi-
tion, is also significantly associated with renal hypertro-those of nondiabetic group, the numbers of glomerular
macrophages in the RAS inhibitor-treated groups in- phy. Although TNF-a has been proposed as a marker
of cardiac hypertrophy [57], an association with renalcreased with time and tended to be higher than those
present in the nondiabetic control group. This discrep- hypertrophy has not been reported previously.
Glomerular macrophage infiltration is an establishedancy between the expression of MCP-1 and the number
of macrophages in the glomeruli indicates that other finding in some forms of glomerulonephritis [7, 8], inter-
stitial nephritis [9], obstructive nephropathy [10], andfactors are likely to contribute to the increased number
of macrophages observed in the glomeruli from the dia- chronic renal allograft failure [58], where the macro-
phages are thought to contribute to renal injury and/orbetic rats. Other monocyte chemotactic factors or in situ
proliferation of macrophages in the glomeruli may be dysfunction. The increased number of macrophages and
the elevated expression of MCP-1 were also reported ininvolved; however, further studies are required to eluci-
date this supposition. Glomerular expression of CSF-1, the remnant kidney model (abstract; Lee et al, J Am Soc
Nephrol 7:1858, 1996) [59], which, like diabetic nephrop-a stimulator of monocyte/macrophage proliferation [41],
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colony stimulating factor-1; DAB, 39,39-diaminobenzidine; DM, diabe-athy, is a model of progressive glomerular sclerosis asso-
tes mellitus; FITC, fluorescein isothiocyanate; ICAM-1, intercellularciated with glomerular capillary hypertension and is not adhesion molecule-1; IIF, indirect immunofluorescence; IL-1b,
usually regarded as being primarily of inflammatory ori- interleukin-1 beta; MCP-1, monocyte chemoattractant protein-1; PAP,
peroxidase-antiperoxidase; PBS, phosphate-buffered saline; RAS, re-gin. Together with our current findings, these observa-
nin-angiotensin system; RT-PCR, reverse transcription-polymerasetions suggest that macrophages, recruited predominantly chain reaction; SBP, systolic blood pressure; STZ, streptozotocin; TBS,
by chemoattractants overexpressed in the glomeruli in Tris-buffered saline; TGF-b, transforming growth factor-beta; TNF-a,
tumor necrosis factor-alpha; VCAM-1, vascular cell adhesionresponse to glomerular hemodynamic abnormalities,
molecule-1.may play a far greater role in the development of glomer-
ular injury of diabetes than hitherto appreciated.
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